Advertisement
Research Article| Volume 56, ISSUE 9, P874-879, September 2003

Health-related quality of life predicts survival, cytomegalovirus disease, and study retention in clinical trial participants with advanced HIV disease

      Abstract

      We tested whether health related quality of life (HRQOL) predicts mortality, development of active cytomegalovirus (CMV) disease, and study retention. We studied 957 patients with CD4 counts <100 cells/mm3 in AIDS Clinical Trials Group Protocol 204, a randomized, double-blind trial comparing three prophylactic regimens against CMV end-organ disease. The MOS-HIV, a brief HRQOL questionnaire, generated physical health summary (PHS) and mental health summary (MHS) scores. We used Cox proportional hazards to predict events by baseline HRQOL, adjusted for treatment, demographics, and CD4. Each point increase in baseline PHS decreased the risk of death by 4%, CMV by 2%, and dropout by 2%. Each point increase in baseline MHS decreased the risk of death by 4% and study dropout by 1%. In conclusion, self-rated physical and mental health demonstrated predictive validity for survival, CMV end-organ disease, and retention in advanced HIV patients. The results show the clinical importance of HRQOL and may facilitate interpretation by clinicians.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Clinical Epidemiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wu A.W
        • Hays R.D
        • Kelly S
        • et al.
        Applications of the medical outcomes study health-related quality of life measures in HIV/AIDS.
        Qual Life Res. 1997; 6: 531-554
        • Schambelan M
        • Mulligan K
        • Grunfeld C
        • et al.
        Recombinant human growth hormone in patients with HIV-associated wasting: a randomized, placebo-controlled trial. Serostim Study Group.
        Ann Intern Med. 1996; 125: 873-882
        • Wisloff F
        • Hjorth M.F
        Health-related quality of life assessed before and during chemotherapy predicts survival in multiple myeloma.
        Br J Haematol. 1997; 97: 29-37
        • Earlam S
        • Glover C
        • Fordy C
        • et al.
        Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases.
        J Clin Oncol. 1996; 14: 171-175
        • Konstam V
        • Salem D
        • Pouleur H
        • et al.
        Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure.
        Am J Cardiol. 1996; 78: 890-895
        • Wu A.W
        • Rubin H.R
        • Mathews W.C
        • et al.
        A health status questionnaire using 30 items from the Medical Outcomes Study: preliminary validation in persons with early HIV infection.
        Med Care. 1991; 29: 786-798
        • Revicki D.A
        • Sorenson S
        • Wu A.W
        Reliability and validity of physical and mental health summary scores from the Medical Outcomes Study HIV Health Survey.
        Med Care. 1998; 36: 126-137
        • Stanton D.L
        • Wu A.W
        • Moore R.D
        • et al.
        Functional status of persons with HIV infection in an ambulatory setting.
        J Acquir Immune Defic Syndr. 1994; 7: 1050-1056
        • Griffiths P.D
        • Feinberg J.E
        • Fry J
        • et al.
        The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123–014 International CMV Prophylaxis Study Group.
        J Infect Dis. 1998; 177: 57-64
        • Feinberg J.E
        • Hurwitz S
        • Cooper D
        • et al.
        A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection.
        J Infect Dis. 1998; 177: 48-56
        • Justice A.C
        • Aiken L.H
        • Smith H.L
        • et al.
        The role of functional status in predicting inpatient mortality with AIDS: a comparison with current predictors.
        J Clin Epidemiol. 1997; 49: 193-201
        • Fried L.P
        • Kronmal R.A
        • Newman A.B
        • et al.
        Risk Factors for 5-year mortality in older adults: the Cardiovascular Health Study.
        JAMA. 1998; 279: 585-592
        • Kutner N.G
        • Lin L.S
        • Fielding B
        • et al.
        Continued survival of older hemodialysis patients: investigation of psychosocial predictors.
        Am J Kidney Dis. 1994; 24: 42-49
        • Shinkai M
        • Bozzette S.A
        • Powderly W
        • et al.
        Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease.
        J Infect Dis. 1997; 175: 302-308
        • Bowen E.F
        • Sabin C.A
        • Wilson P
        • et al.
        Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease.
        AIDS. 1997; 11: 889-893
        • Spector S.A
        • Hsia K
        • Crager M
        • et al.
        Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS.
        J Virol. 1999; 73: 7027-7030
        • Goldman A.I
        • Holcomb R
        • Perry H.M
        • et al.
        Can dropout and other noncomplicance be minimized in a clinical trial? Report from the Veterans Administrative National Heart, Lung and Blood Institute Cooperative Study on Antihypertensive Therapy. Mild hypertension.
        Control Clin Trials. 1982; 3: 75-89
        • Cramer J.A
        • Collins J.F
        • Mattson R.H
        Can categorization of patient background problems be used to determine early termination in a clinical trial?.
        Control Clin Trials. 1988; 9: 47-63
        • Bender B.G
        • Ikle D.N
        • DuHamel T
        • et al.
        Retention of asthmatic patients in a longitudinal clinical trial.
        J Allergy Clin Immunol. 1997; 99: 197-203
        • Orr P.R
        • Blackhurst D.W
        • Hawkins B.S
        Macular Photocoagulation Study Group. Patient and clinic factors predictive of missed visits and inactive status in a multicenter clinical trial.
        Control Clin Trials. 1992; 13: 40-49
        • Idler E.L
        • Kasl S.V
        Self-ratings of health: do they also predict change in functional ability?.
        J Gerontol Soc Sci. 1995; 50B: S344-S353
        • Ford D.E
        • Mead L.A
        • Chang P.P
        • et al.
        Depression is a risk factor for coronary artery disease in men: the precursors study.
        Arch Intern Med. 1998; 158: 1422-1426
        • Palella F.J
        • Delaney K.M
        • Moorman A.C
        • et al.
        Declining morbidity and mortality among patients with advanced human immunodeficiency virus syndrome.
        N Engl J Med. 1998; 338: 853-860
        • Centers for Disease Control
        Update: Trends in AIDS incidence–United States, 1996.
        MMWR. 1997; 46: 861-867
        • Wu A.W
        • Revicki D.A
        • Jacobson D.L
        • et al.
        Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV).
        Qual Life Res. 1997; 6: 481-493